Drugs / [177Lu]Lu-PSMA-XT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07096128 | Aug 2024 → May 2026 overdue | castration-resistant prostate carcinoma | Jinming Zhang | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-PSMA-XT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07096128 ↗ |
| Modality | Other / unclassified | “\[177Lu\]Lu-PSMA-XT is a radioligand therapy” NCT07096128 ↗ |